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Abstract Methylation of the MGMT promoter is sup-
posed to be a predictive and prognostic factor in glioblas-
toma. Whether MGMT promoter methylation correlates
with tumor response to temozolomide in low-grade gliomas
is less clear. Therefore, we analyzed MGMT promoter
methylation by a quantitative methylation-specific PCR in
22 patients with histologically verified low-grade gliomas
(WHO grade II) who were treated with temozolomide
(TMZ) for tumor progression. Objective tumor response,
toxicity, and LOH of microsatellite markers on chromo-
somes 1p and 19q were analyzed. Histological classification
revealed ten oligodendrogliomas, seven oligoastrocytomas,
and five astrocytomas. All patients were treated with TMZ
200 mg/m2 on days 1–5 in a 4 week cycle. The median
progression-free survival was 32 months. Combined LOH
1p and 19q was found in 14 patients; one patient had LOH 1p
alone and one patient LOH 19q alone. The LOH status could
not be determined in two patients and was normal in the
remaining four. LOH 1p and/or 19q correlated with longer
time to progression but not with radiological response to
TMZ. MGMT promoter methylation was detectable in 20
patients by conventional PCR and quantitative analysis
revealed the methylation status was between 12 and 100%.
The volumetric response to chemotherapy analyzed by MRI
and time to progression correlated with the level of MGMT
promoter methylation. Therefore, our retrospective case
series suggests that quantitative methylation-specific PCR
of the MGMT promoter predicts radiological response to
chemotherapy with TMZ in WHO grade II gliomas.
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Introduction
Low-grade gliomas are slow-growing tumors that have a
peak incidence around age 40 years. Maximum feasible
resection is the treatment of choice, despite the lack of
randomized trials supporting that concept. Although
extended survival after resection is typical, most patients
eventually succumb to recurrent disease. Upfront adjuvant
radiation therapy (RT) modestly improves progression-free
survival but not overall survival compared with RT delayed
until recurrence [1], and application of doses of 59.4 Gy or
higher is no more effective than doses as low as 45 Gy
[2, 3]. On the basis of on this evidence and because of
concerns about the potential long-term neurotoxicity of RT
this treatment is usually delayed until recurrence [4, 5].
Chemotherapy with oral temozolomide has clearly become
a treatment option for WHO grade II glioma patients
[6–10], with excellent response rates, especially in oligo-
dendroglial tumors, which typically show loss of
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heterozygosity of chromosomes 1p/19q [9, 10]. TMZ and
RT are currently being compared in a multicenter, ran-
domized trial (EORTC 22033, 26033). In fact, it is unclear
when and how to incorporate chemotherapy into the
treatment strategy for low-grade gliomas. Molecular
markers may help in selecting patients who are likely to
benefit from chemotherapy. LOH 1p/19q helps to predict
response to chemotherapy; it is, however, also a prognostic
marker in the absence of chemotherapy [11, 12] and the
genes and signaling pathways that are associated with this
loss are yet to be determined.
TMZ is a pro-drug that, when hydrolyzed, modifies the
DNA at several sites, most commonly generating N7-
methylguanine and N3-methyladenine, which constitute
nearly 90% of the total methylation events, and to a lesser
extent O6 methylation events. Despite the fact that
O6-methylguanine accounts only for about 5% of all meth-
ylation events, adducts at the O6 position of guanine are
particularly mutagenic and cytotoxic, and probably respon-
sible for the cytotoxic effect of TMZ [13]. O6-Methylgua-
nine methyltransferase (MGMT) is a DNA-repair protein
that rapidly reverses alkylation (including methylation) at
the O6 position of guanine, thereby neutralizing the cytotoxic
effects of alkylating agents such as TMZ. High levels of
MGMT activity in tumor tissue are associated with resis-
tance to alkylating agents [14]. MGMT gene silencing by
promoter methylation results in reduced MGMT expression
in tumor cells, and therefore, MGMT promoter methylation
is associated with longer survival of glioblastoma patients
treated with TMZ. However, MGMT promoter methylation
is also a prognostic factor in the absence of adjuvant che-
motherapy with alkylating agents [15, 16]. Other authors
have shown that a multigene profile may be superior to
MGMT methylation status in predicting response to TMZ in
glioblastoma patients and that MGMT status did not signif-
icantly correlate with overall survival in multivariate anal-
ysis [17]. The role of MGMT activity in predicting response
to chemotherapy in low-grade gliomas is even less clearly
established.
Several methods for measuring MGMT levels within
tumors have been described (reviewed elsewhere [18]).
The MGMT protein can be detected in tissue samples by
immunohistochemistry, enzyme activity can be measured
by high-performance liquid chromatography (HPLC), and
epigenetic silencing of the MGMT gene by promoter
methylation can be assessed by using a methylation-spe-
cific polymerase chain reaction assay. We performed a
retrospective study to analyze the correlation between
MGMT promoter methylation, radiological response, and
time to progression in a series of WHO grade II glioma
patients treated with TMZ. The MGMT methylation status
was assessed using a primer extension-based quantitative
polymerase chain reaction.
Materials and methods
Patients
Patients with WHO grade II glioma, diagnosed at our
institution between 1989 and 2007 and treated with TMZ
between 1999 and 2007, were included into this retrospec-
tive study. Patients with radiological signs of progression to
high grade gliomas (e.g., a new contrast enhancing lesion) at
start of TMZ treatment were excluded.
Outcome
Magnetic resonance images (MRI) were obtained before
therapy and every six months thereafter. Digitized MRIs
were analyzed using Sectra IDS5 10.2 Software (Sectra
Imtec, Linko¨ping, Sweden). Tumor volumes were mea-
sured on the basis of the entire region of hyperintensity
(compared with normal brain) in T2-weighted and FLAIR
MRIs. Tumor response was defined as minor (MR, reduc-
tion by C25 to \50% of the initial tumor volume), partial
(PR, C50%), and complete (CR, no residual tumor). Pro-
gressive disease was defined as an increase in tumor
volume by C25%, independent of contrast enhancement.
DNA extraction
Representative areas of the tumor were excised from for-
malin-fixed paraffin-embedded tissue and DNA was
extracted using the EZ1 tissue kit (Qiagen, Hombrechtikon,
Switzerland) according the manufacturer’s procedure.
Tissues were heat-treated in lysis buffer for 10 min at 95C
prior to proteinase K digestion. Reference DNA was
extracted from the patient’s EDTA peripheral blood using
the same kit. Written informed consent for the use of
material for genetic analyses on tumor and blood was
obtained from patients.
Histology
The pathologic assessment was performed by two board-
certified neuropathologists as described earlier [11].
In brief, the tumor was called oligoastrocytoma if a
fibrillary, gemistocytic, or protoplasmatic component was
well developed and if at least one high-power field was
found in the specimen that, if considered alone, would have
warranted diagnosis of an oligodendroglioma. The tumor
was considered an oligodendroglioma if this component
was exclusive or largely predominant and no astroglial
differentiation was present except for the minigemistocytes
and gliofibrillary oligodendrocytes frequently present in
typical oligodendrogliomas.
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Loss of heterozygosity on 1p/19q
Genotypes for multiple loci were determined by polymerase
chain reaction using fluorescent primers tagged with HEX
or FAM (Microsynth, Balgach, Switzerland) for microsat-
ellite markers on chromosome 1p36 (D1S468, D1S1612,
D1S228, D1S214) and chromosome 19q13 (D19S219,
D19S412, D19-HRC). The microsatellite markers spanned
over the regions 1p36.21–1p36.33 and 19q13.31–19q13.41
and were selected according to Smith et al. [12]. PCR
amplification was performed in separate reactions. Analysis
of PCR products was performed by capillary electropho-
resis using a genetic analyzer (ABI Prism 3100-Avant;
Applied Biosystems, Rotkreuz, Switzerland) and GeneM-
apper software 4.0. LOH was determined by measuring the
peak area from each of the alleles produced from the tumor
and corresponding normal DNA. Diagnostic criteria for
LOH required the calculated ratio of the peak areas to be
less than 0.5.
MGMT promoter methylation
Bisulfite treatment was performed using the EZ DNA
modification kit according to the manufacturer’s procedure
(Zymo, Orange, CA, USA). The modified DNA was eluted
with 10 ll M-elution buffer and diluted with 10 ll water.
Qualitative methylation-specific PCR was performed using
primer pairs specific for the methylated (M_forward_HEX
and M_rv) or unmethylated (U_forward_FAM and U_rv)
form of the MGMT promoter, and 2 ll bisulfite-treated DNA.
Forward primers were tagged with HEX or FAM (Micros-
ynth). The sequence of the primers used are reported else-
where [15]. PCR products were analyzed by capillary
electrophoresis as described above.
Establishment and validation of the quantitative methyl-
ation-specific assay are described elsewhere (Vassella et al.
back to back submission). Briefly, bisulfite-treated DNA
was amplified by PCR using the primer pair MU_forward
(50-GGATATGTTGGGATAGTT-30) and MU_rv (50-ACG
CCTACAAAACCACTC-30) and 2 ll bisulfite-treated
DNA. The PCR product was diluted 1:10 with water and
subjected to a multiplex primer extension using primers
M_forward_HEX and U_forward_FAM. Analysis was
performed by capillary electrophoresis. The percentage of
methylated DNA was determined by measuring the peak
area for methylated and unmethylated DNA and normalized
to a control containing equal amounts of methylated and
unmethylated DNA, which was performed in the same
experiment.
The median of MGMT promoter methylation was used
to define the cut off between high and low methylation.
Statistical analysis
Patient and therapy-related factors were tested for a pos-
sible correlation with response under TMZ therapy. Fish-
er’s exact test based on cross-tables was performed to test
the influence of age (\40 years and [40 years), gender,
presence of any oligodendroglial component, 1p36 and
19q13 status, and tumor volume (\70 cm3 and [70 cm3).
Linear regression was used to analyze the interaction of
MGMT methylation and volumetric response. Kaplan–
Meier curves were compared using the Log-rank test. The
level of statistical significance was set at P \ 0.05 for a
two-tailed hypothesis. GraphPad Prism 5 software (San
Diego, CA, USA) was used for statistical analysis.
Results
Patient characteristics
The demographic details of the study cohort are presented
in Table 1. There were thirteen males and nine females.
The median age was 53 years. All patients had histologi-
cal confirmation of grade II gliomas (ten oligodendroglio-
mas, seven oligoastrocytomas, and five astrocytomas).
Median time from diagnosis to treatment with TMZ was
59.6 months (range 2–220 months). Seven patients under-
went prior subtotal resection, six patients had prior radio-
therapy, but none of the patients had received chemotherapy
before. All patients demonstrated evidence of neurological
progression. This included seizure exacerbation in 18
patients, aphasia in seven patients, cognitive decline in nine
patients, paralysis in one patient, and vertigo in one patient.
All patients received TMZ chemotherapy 200 mg/m2 on
days 1–5 in a 28 days cycle. The median duration of TMZ
treatment was 12 months. Seven patients were changed to
a dose-dense TMZ scheme (14/21 days 100 mg/m2) after
progression. Two of these seven patients had a radiological
MR. Seventeen of the 22 patients did not receive steroids
at any time during TMZ treatment. Of the remaining five
patients, three had a stable dose and steroids could be
reduced in two patients during TMZ treatment.
Toxicity
Generally, TMZ was well tolerated. Adverse events are listed
in Table 2. Major toxicity was limited to myelosuppression.
Two patients experienced grade 3–4 leucopenia and five
patients grade 3–4 thrombocytopenia. Non-hematological
adverse events were mild (grade 1–2).
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Treatment outcome
Median progression-free survival of the study cohort was
32 month (95% CI, 8.1–52.6). Progression was defined as
increase in tumor volume of [25%. Twelve of the 22
patients showed signs of contrast enhancement at the time of
volumetric progression (55%). Progression-free survival
(PFS) at 12 and 24 months was 81 and 61%, respectively
(Fig. 1a). From the start of treatment with TMZ median
overall survival was 50 month (95% CI, 18.5–77.3, Fig. 1b).
Neither PFS nor OS differed significantly by tumor type
(Fig. 1c, d).
Marked clinical improvement was documented in 14
patients (64%). Clinical stability was reported in eight
patients (36%). None of the patients demonstrated evidence
of neurological progression during treatment.
The objective response rate by MRI criteria was 59%
(6 PRs and 7 MRs). Eight patients maintained stable
disease (SD), and one patient developed progressive dis-
ease (PD). An example of the radiological tumor analy-
sis for a responding patient is shown in Fig. 2 a, b.
Consecutive areas were used to calculate the volume.
There was no significant association between age
(\40 years and [40 years, P = 0.617), gender (P =
0.674), prior radiation (P = 0.411) presence of any oli-
godendroglial component (P = 0.609), tumor volume
(\70 cm3 and [70 cm3, P = 1.000), and radiological
response. The median best volumetric change during
Table 1 Patient characteristics
Number %
No. of patients 22
Gender
Male 13 59
Female 9 41
Age, years
Median 53
Range 27–72
Time from biopsy to
treatment (month)
Median 4.5
Range 1–148
Histology
Oligodendroglioma 10 45
Oligoastrocytoma 7 32
Astrocytoma 5 23
Prior surgery
Biopsy only 15 68
Subtotal resection 7 32
Prior radiotherapy 6 27
Tumor volume (cm3)
Median 69.7
Range 21–332
Side
Left 14 63
Right 7 32
Right and left 1 5
Tumor location
Frontal lobe 9 41
Insula 1 5
Temporal lobe 4 18
Parietal lobe 8 36
Clinical symptoms
Seizure 18 82
Aphasia 7 32
Cognitive deficiency 9 41
Paralysis 1 5
Vertigo 1 5
WHO PS at start
of treatment
Median 0
Range 0–2
Cycles of TMZ
Median 12
Range 4–22
TMZ regimen (pts)
Day 1–5 22 100
Dose dense 7 32
Table 2 Toxicity
Grades 1–2 Grades 3–4
Event No of patients % No of patients %
Blood/bone marrow
Anemia 13 59
Leucopenia 9 41 2 9
Thrombocytopenia 3 14 5 23
Laboratory
ALT/AST 1 5
Bilirubin 2 9
Glucose 6 27
Hyponatremia 1 5
Hypernatremia 5 23
Gastrointestinal
Nausea/vomiting 14 64
Constipation 9 41
Others
Mucositis 2 9
Rash/desquamation 2 9
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therapy with TMZ was a 25.5% reduction in tumor vol-
ume compared with pre-treatment MRI. Patients with a
good radiological response ([25.5% reduction) had
improved progression-free survival compared with patients
with poor radiological response (\25.5% reduction;
Fig. 4a, HR 0.14; 95% CI 0.04–0.53, P = 0.004) .
LOH status of 1p/19q and treatment outcome
Twenty tumor and blood DNA pairs were available for
1p/19q LOH analysis (Fig. 2). LOH on both 1p and 19q
was detected in 14 patients (64%). A radiographic response
was observed for eight of those patients (4 PRs and 4
MRs), five patients maintained SD, and one patient pro-
gressed. Two patients had either LOH 1p or 19q only. Both
had an MR under TMZ treatment. One of the remaining
four patients with intact 1p and 19q had a PR; for the other
three patients SD was the maximum response. There was
no significant association between 1p LOH and radio-
graphic response (P = 0.303, not shown). However, time
to radiological progression was significantly longer for
patients with LOH 1p and/or 19q than for patients with
intact chromosomes 1p and 19q in their tumor (Fig. 4b; HR
0.11; 95% CI 0.01–0.90, P = 0.039).
MGMT promoter methylation and tumor response
Methylation-specific PCR was performed for all tumor
samples. MGMT promoter methylation was detectable in
19 patients by conventional PCR. For two patients with
negative MGMT promoter methylation SD was their
maximum response; one patient had an MR. The associa-
tion between MGMT promoter methylation and radio-
graphic response did not reach statistical significance
(P = 0.544, not shown).
Quantitative analysis of MGMT promoter methylation
revealed methylation levels between 12 and 100%. The
three tumor samples that were negative in conventional
methylation-specific PCR similarly revealed 0% methyla-
tion in the quantitative assay. We next analyzed the corre-
lation between the level of MGMT promoter methylation
and volumetric response to chemotherapy after 6 months
and at the time point of maximum response as a continu-
ous variable. The level of MGMT methylation correlated
with radiographic response after 6 months of therapy (P =
0.012, Fig. 3a) and with maximum response to chemo-
therapy (P = 0.045, Fig. 3b).
The median MGMT promoter methylation level in the
22 patients analyzed was 75%. Patients with high MGMT
promoter methylation levels ([75%) had a significantly
longer time to progression than patients with methylation
levels below 75% (HR 0.20, 95% CI 0.06–0.70, P = 0.012,
Fig. 4c).
Discussion
There is increasing evidence that chemotherapeutic agents
used for treatment of high-grade gliomas, for example PCV
or TMZ, are also active against low-grade glioma in adults
Fig. 1 Progression free and
overall survival. a PFS for all
patients (n = 22). b OS for all
patients (n = 22). c PFS and
d OS separated by tumor type
oligodendrogloma (OD,
n = 10), oligoastrocytoma (OA,
n = 7), and pure astrocytoma
(A, n = 5). MRI were
performed before therapy and
every six months thereafter.
Progressive disease was defined
as an increase in tumor volume
by C25%, independent of
contrast enhancement.
(\ censored event)
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[6–10, 19]. This is confirmed in our study—a clinical
improvement in 64% and a radiological response in 59%
(PRs and MRs) of treated patients, with good tolerability.
The median PFS was 32 months and compares favor-
ably with published studies of TMZ in low-grade gliomas,
in which the median PFS ranged from 10 to 31 months
[6, 7, 20, 21]. This may largely reflect the selection of good
prognostic patients in our study. Recently, Kesari et al.
showed in a prospective phase II study that protracted daily
TMZ (7 weeks on/4 weeks off) results in a radiological
response rate of 20% (PR) and a median PFS of 38 month
[22]. These promising results may be the consequence of
increased dose density of protracted daily TMZ versus
Fig. 2 Radiological response of low-grade glioma. The volumetric
response in MRI was analyzed every 6 months on the basis of the
entire region of hyperintensity (compared with normal brain) in T2-
weighted and FLAIR MRIs and compared with the volume before
treatment. One example of the area analysis in T2-weighted MRI
before (a) and after treatment is shown (b). Forest plot of the
dependence of radiological response on LOH 1q and/or 19p (c) after
6 months of treatment and (d) maximum response. LOH 1p and 19q
were analyzed from tissue samples at diagnosis
Fig. 3 Correlation of MGMT promoter methylation and radiological
response (a) after 6 months of treatment and (b) maximum response.
Quantitative MGMT promoter methylation was analyzed as described
by Vasella et al. (accompanying manuscript) from tissue samples at
diagnosis. The volumetric response in MRI was analyzed every
6 months on the basis of the entire region of hyperintensity (compared
with normal brain) in T2-weighted and FLAIR MRIs and compared
with the volume before treatment
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standard 5 day TMZ or, potentially, of MGMT depletion in
the tumor during continuous exposure to TMZ [23].
Although published studies and our own retrospective
study confirm the clinical efficacy of TMZ in low-grade
gliomas, it remains open how to incorporate chemother-
apy in the treatment algorithm of these tumors. Currently,
chemotherapy is primarily used for recurrent disease. The
role of chemotherapy in the initial management of low-grade
gliomas is under investigation in several large ongoing
studies. Identification of patients who benefit from treat-
ment has a major impact on patient care. Several predictive
factors for the response to chemotherapy have been identi-
fied in gliomas. These include histological characteristics
such as oligo-component versus non-oligo tumors, and
molecular profiles such as LOH on 1p/19q and MGMT
promoter methylation [9, 10, 24]. Of note, most of these
characteristics were defined in retrospective analysis and are
not strictly predictive of the response under chemotherapy
but are also prognostic, independent of the treatment [11,
12]. Other genetic factors such as IDH1 mutation may be
prognostic but not predictive for response to TMZ [25].
In this study we correlated known predictive and prog-
nostic molecular markers with radiological response. Our
series clearly indicates selection by histological character-
istics, resulting in 77% tumors with an oligodendroglial
component. This also explains the high frequency of LOH
on 1p and/or 19q, which was found in 82% of the tumors
analyzed [26]. Similarly, MGMT promoter methylation was
found in 86% of the tumor samples analyzed, which is also
higher than would be expected in an unselected population
of patients with low-grade gliomas. Whether or not MGMT
promoter methylation and LOH status are causally linked or
MGMT promoter methylation is an independent predictive
marker for WHO grade II gliomas is controversial [26–28].
As a consequence of the limited sample size and the
selection of oligo-tumors in our study, histological features
could not be validated as predictive markers. Our data
confirmed for low-grade glioma that patients with LOH1p/
19q in the tumor clearly have longer progression-free sur-
vival than patients with tumors with intact 1p/19q. In con-
trast, LOH 1p and 19q was not correlated with radiological
response to TMZ treatment. However, although our study
selected for patients with good prognostic and probably
predictive markers for the treatment with TMZ, treatment
outcome varied substantially within this group. This finding
underscores the need for additional biomarkers able to pre-
dict the level of response to TMZ. Although each tumor cell
has a defined quantity of MGMT protein, the level can vary
substantially within a tumor. MGMT stoichiometrically
removes TMZ-induced methylation adducts from guanine
residues [29]. Therefore, the effect of MGMT depends on
Fig. 4 Volumetric response, 1p and 19q deletion status, and MGMT
promoter methylation level and PFS. a PFS of patients were separated
into a group with a radiological response better than the median
reduction of 25.5% (vol. response high, n = 11) and a group of
patients with poor radiological response (below 25.5% reduction in
tumor volume (vol. response low-neg, n = 11; log rank P = 0.004).
b PFS for patients with 1p and/or 19q deletion (n = 17) and patients
with intact 1p and 19q (n = 3; log rank P = 0.039). (c) PFS for
patients with a high level of MGMT promoter methylation ([75% =
median, n = 11) and patients with low or negative MGMT pro-
moter methylation level (n = 11, log rank P = 0.012) (\ denotes a
censored event)
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the level of expression within a tumor cell and on the het-
erogeneity of the tumor. In fact, a recent study in glio-
bloastoma showed that the degree of promoter methylation
as analyzed by pyrosequencing correlates with progression-
free and overall survival [30]. We have now quantitatively
analyzed the level of methylation of the MGMT promoter in
our tumor samples of low-grade gliomas. The volumetric
response to chemotherapy correlated with the level of
MGMT promoter methylation. In addition, time to pro-
gression was significantly longer in the group with high level
of MGMT promoter methylation than in the group with low
level MGMT promoter methylation. Molecular analysis was
performed on tissue samples taken at diagnosis, which is
1–148 months (median 4.5 months, Table 1) before the start
of treatment with TMZ. However, none of the patients
received alkylating agents before treatment with TMZ. In
addition, currently there is no indication that MGMT pro-
moter methylation varies over time in the absence of che-
motherapy. Therefore, our data suggest that the level of
MGMT promoter methylation at diagnosis can serve as a
predictive marker for a therapy that is applied several
months later. In summary, our data indicate that in tumors
with MGMT promoter methylation, quantitative analysis of
the level of methylation enables further prediction of the
magnitude of response and time to progression.
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